Navigation Links
Penn's Abramson Cancer Center part of major phase III study for myeloma
Date:11/21/2007

PHILADELPHIA Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. The findings show that with the oral drug lenalidomide (REVLIMID), in combination with the steroid dexamethasone, patients significantly improved by all measures where previous treatments had failed including a median survival of nearly three years the longest median survival known for this difficult to treat patient group. Edward A. Stadtmauer, MD, Director of the Abramson Cancer Center Bone Marrow and Stem Cell Transplant Program and lead investigator from Penn, was part of the U.S. study published today in the New England Journal of Medicine alongside a companion study from Europe showing similar results.

"Myeloma, also known as multiple myeloma, is a growing interest and concern of cancer clinicians and researchers," said Stadtmauer. "While most U.S. cancer diagnoses are decreasing, statistics show that the number of myeloma diagnoses is increasing, particularly in younger patients. This disturbing trend fuels the urgency to discover effective treatments to fight this disease. This study shows that this new class of drugs is a critical advance toward meeting that need."

REVLIMID (lenalidomide) from Celgene, an oral medication which treats without the ravages of chemotherapy, is the first in a new class of medications called immunomodulatory drugs (IMiDs). It works by attacking both the cancer cell and the micro-environment in which it lives in the bone marrow, thereby stopping the cells ability to adhere to the wall of tissues where they will grow. REVLIMID may also inhibit cancer cells ability to hide from the bodys natural killer cells in the immune system by stopping angiogenesis the growth of blood vessels that penetrate into and feed cancerous tumors causing them to proliferate.

In both the US and European studies, patients for whom all previous treatments had failed were given either lenalidomide plus dexamethasone a potent synthetic steroid or dexamethasone with placebo. These trials were designed to investigate the effectiveness and safety of cyclic dosing of REVLIMID at 25mg combined with high-does dexamethasone (HDD) compared with placebo and HDD in previously treated patients with multiple myeloma. A total of 705 patients were enrolled in 97 sites internationally. Patients in both trials had been heavily treated prior to enrollment, many having failed three or more rounds of chemo and/or radiation therapy. In addition, more than 50 percent of patients enrolled had undergone stem cell transplantation. In these new studies REVLIMID plus dexamethasone achieved superior results compared to dexamethasone alone regardless of the history of treatment, including the media survival of nearly three years. Such positive patient response suggests that treatment with REVLIMID early in the course of the disease may be beneficial. These findings have caused a change in the official physician guidelines for multiple myeloma which were recently updated to add REVLIMID as an initial treatment, instead of waiting until other treatments have failed.

In Europe and the US, REVLIMID is being used to threat myeloma. In the US it is also approved for a pre-leukemia condition called myelodysplastic syndrome (MDS). It is also being tested in other leukemias, lymphomas, and solid tumors.

The last five to ten years have been the most wonderful time to be a physician treating multiple myeloma, thanks to advances like lenalidomide, said Stadtmauer. Twenty, thirty years ago, there wasnt much we could do for these patients. We couldnt really treat the disease effectively so we tried to treat the symptoms with only two or three types of chemotherapy and radiation, which of course have their own negative side-effects. Now, we have this new, highly effective class of drugs with very low side effects. Before, we hoped for a positive response in patients. Now, we expect one. Adds Stadtmauer, Thanks to new agents like lenalidomide, weve been able to convert this disease from a killer to more of a chronic illness.


'/>"/>

Contact: Olivia Fermano
Olivia.Fermano@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
2. Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke-Free Law in Pennsylvania
3. NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania
4. Pennsylvania Department of Aging Receives Grant to Improve Alzheimers Support
5. Pennsylvania Needs More Lung Cancer Research
6. Saint Vincent Health System of Erie, Pennsylvania Named One of AARP 2007 Best Employers for Workers Over 50
7. Pennsylvania Game Commission Announces EHD Confirmed in Allegheny and Westmoreland Counties
8. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
9. Pennsylvania Trauma Systems Foundation Accreditation Status for Trauma Centers
10. Health Secretary Urges Pennsylvanians to Get a Flu Shot
11. Governor Rendell Calls for Prompt Action on Prescription for Pennsylvania, Cover All Pennsylvanians Health Care Reforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... SC (PRWEB) , ... February 28, 2017 , ... ... is the premiere organization in North America for the scientific development, healthcare training ... its 2017 Annual Meeting & Scientific Session on September 16-17 in Greenville, SC ...
(Date:2/28/2017)... Salt Lake City, Utah (PRWEB) , ... February 28, 2017 , ... ... Heart Month is a time for everyone to reaffirm their commitment to improving cardiovascular ... leading cause of death for men and women. Every year, one in four deaths ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... from 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville is ... performance analytics, and engagement strategies. , The discussion will include best practices for ...
(Date:2/27/2017)... Austin, TX (PRWEB) , ... February 27, 2017 , ... ... of a large medical group. But his impoverished upbringing and life experiences could have ... to Become a Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. ...
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... Markets has announced the addition of the "Ovarian Cancer Drugs Price ... The latest research Ovarian Cancer Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Ovarian Cancer ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. ... it will report its fourth quarter and year ... March 7, 2017.  Rigel senior management will follow ... webcast at 5:00pm Eastern Time (2:00pm Pacific Time) ... can access the live conference call by dialing ...
(Date:2/28/2017)... , February 27, 2017 ... BioMedical assets for potential ... LOI contemplates capital infusion into Amarantus to assist ... Amarantus names four new appointees to its Board of Directors and ... SeD Biomedical Inc. (SeD Biomedical) , a ...
Breaking Medicine Technology: